港股异动 | 复宏汉霖(02696)高开逾4% PD-L1/VEGF双抗启动一线NSCLC 2/3期临床

智通财经
Oct 09

智通财经APP获悉,复宏汉霖(02696)高开逾4%。截至发稿,涨4.64%,报53.0港元,成交额4.77万港元。

消息面上,10月8日,复宏汉霖在Clinicaltrials.gov网站上注册了PD-L1/VEGF双抗HLX37+化疗一线治疗晚期NSCLC的2/3期临床试验。该2/3期临床试验与K药+化疗标准疗法头对头对照,计划入组1438例受试者,预计2030年底初步完成。

值得注意的是,9月23日,复宏汉霖宣布与美国生物技术公司Amberstone达成合作:以不超过400万美元的首付款,引进两款基于T-MATE™平台的条件激活型T细胞衔接器(TCE),交易最高潜在对价约8.88亿美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10